Novartis AG ADR

$112.14
(as of Apr 25, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Novartis AG ADR

Stock Price
$112.14
Ticker Symbol
NVS
Exchange
NYSE

Industry Information for Novartis AG ADR

Sector
Healthcare
Industry
Drug Manufacturers - General

Company Description for Novartis AG ADR

Country
USA
Full Time Employees
75,883

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Fundamentals for Novartis AG ADR

Market Capitalization
$219,570,749,440
EBITDA
$20,661,999,616
Dividends per Share
$3.86
P/E Ratio
18.94
Forward P/E Ratio
13.62
Earnings per Share
$5.87
Earnings per Share Estimate Next Year
Profit Margin
23.09%
Shares Outstanding
1,975,090,048
Percent Owned by Insiders
0.00%
Percent Owned by Institutions
6.71%
52-Week High
52-Week Low

Technical Indicators for Novartis AG ADR

50-Day Moving Average
200-Day Moving Average
RSI
56.45
2.5

Analyst Ratings for Novartis AG ADR

Strong Buy
0
Buy
2
Hold
9
Sell
0
Strong Sell
2

News About Novartis AG ADR

Apr 26, 2025, 10:15 AM EST
President Donald Trump's macroeconomic policies are taking center stage on Wall Street. See more.
Apr 25, 2025, 1:00 AM EST
Earnings season is now in full swing, with a number of key companies due to report in the coming week, including four of the Magnificent 7 tech giants in focus. See more.
Apr 23, 2025, 12:51 PM EST
(Updates with response from European Commission in the last three paragraphs.) See more.
Apr 23, 2025, 9:56 AM EST
Novartis (NVS) Chief Executive Vas Narasimhan and Paul Hudson, his counterpart at Sanofi (SNY) said See more.